These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 18653704

  • 21. Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Ueki S, Yamashita K, Aoyagi T, Haga S, Suzuki T, Itoh T, Taniguchi M, Shimamura T, Furukawa H, Ozaki M, Umezawa K, Todo S.
    Transplantation; 2006 Dec 27; 82(12):1720-7. PubMed ID: 17198266
    [Abstract] [Full Text] [Related]

  • 22. Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells.
    Wakamatsu K, Nanki T, Miyasaka N, Umezawa K, Kubota T.
    Arthritis Res Ther; 2005 Dec 27; 7(6):R1348-59. PubMed ID: 16277688
    [Abstract] [Full Text] [Related]

  • 23. Inhibition of macrophage activation and phagocytosis by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Suzuki E, Umezawa K.
    Biomed Pharmacother; 2006 Nov 27; 60(9):578-86. PubMed ID: 16978829
    [Abstract] [Full Text] [Related]

  • 24. Synergistic effect of 5-azacytidine and NF-κB inhibitor DHMEQ on apoptosis induction in myeloid leukemia cells.
    Togano T, Nakashima M, Watanabe M, Umezawa K, Watanabe T, Higashihara M, Horie R.
    Oncol Res; 2012 Nov 27; 20(12):571-7. PubMed ID: 24139415
    [Abstract] [Full Text] [Related]

  • 25. Pleiotropic potential of dehydroxymethylepoxyquinomicin for NF-κB suppression via reactive oxygen species and unfolded protein response.
    Nakajima S, Kato H, Gu L, Takahashi S, Johno H, Umezawa K, Kitamura M.
    J Immunol; 2013 Jun 15; 190(12):6559-69. PubMed ID: 23690471
    [Abstract] [Full Text] [Related]

  • 26. Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer.
    Suzuki K, Aiura K, Matsuda S, Itano O, Takeuchi O, Umezawa K, Kitagawa Y.
    Clin Exp Metastasis; 2013 Apr 15; 30(4):381-92. PubMed ID: 23111540
    [Abstract] [Full Text] [Related]

  • 27. A novel nuclear factor κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates puromycin aminonucleoside-induced nephrosis in mice.
    Shimo T, Adachi Y, Yamanouchi S, Tsuji S, Kimata T, Umezawa K, Okigaki M, Takaya J, Ikehara S, Kaneko K.
    Am J Nephrol; 2013 Apr 15; 37(4):302-9. PubMed ID: 23548793
    [Abstract] [Full Text] [Related]

  • 28. The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism.
    Lampiasi N, Azzolina A, Umezawa K, Montalto G, McCubrey JA, Cervello M.
    Cancer Lett; 2012 Sep 01; 322(1):35-44. PubMed ID: 22343223
    [Abstract] [Full Text] [Related]

  • 29. Dehydroxymethylepoxyquinomicin (DHMEQ), a novel NF-kappaB inhibitor, inhibits allergic inflammation and airway remodelling in murine models of asthma.
    Shimizu K, Konno S, Ozaki M, Umezawa K, Yamashita K, Todo S, Nishimura M.
    Clin Exp Allergy; 2012 Aug 01; 42(8):1273-81. PubMed ID: 22805475
    [Abstract] [Full Text] [Related]

  • 30. Antitumor effect of a novel nuclear factor-kappa B activation inhibitor in bladder cancer cells.
    Horiguchi Y, Kuroda K, Nakashima J, Murai M, Umezawa K.
    Expert Rev Anticancer Ther; 2003 Dec 01; 3(6):793-8. PubMed ID: 14686701
    [Abstract] [Full Text] [Related]

  • 31. Antineoplastic Effects of NF-κB Inhibition by DHMEQ (Dehydroxymethylepoxyquinomicin) Alone and in Co-treatment with Radio-and Chemotherapy in Medulloblastoma Cell Lines.
    Ramos PMM, Pezuk JA, Castro-Gamero AM, Oliveira HF, Scrideli CA, Umezawa K, Tone LG.
    Anticancer Agents Med Chem; 2018 Dec 01; 18(4):541-549. PubMed ID: 29141555
    [Abstract] [Full Text] [Related]

  • 32. Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent.
    Katsman A, Umezawa K, Bonavida B.
    Drug Resist Updat; 2007 Dec 01; 10(1-2):1-12. PubMed ID: 17306602
    [Abstract] [Full Text] [Related]

  • 33. Dehydroxymethylepoxyquinomicin (DHMEQ) therapy reduces tumor formation in mice inoculated with tax-deficient adult T-cell leukemia-derived cell lines.
    Ohsugi T, Kumasaka T, Okada S, Ishida T, Yamaguchi K, Horie R, Watanabe T, Umezawa K.
    Cancer Lett; 2007 Nov 18; 257(2):206-15. PubMed ID: 17764832
    [Abstract] [Full Text] [Related]

  • 34. A small molecule inhibitor of NF-kappaB, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells.
    Wong JH, Lui VW, Umezawa K, Ho Y, Wong EY, Ng MH, Cheng SH, Tsang CM, Tsao SW, Chan AT.
    Cancer Lett; 2010 Jan 01; 287(1):23-32. PubMed ID: 19560263
    [Abstract] [Full Text] [Related]

  • 35. Antitumor effect of dehydroxymethylepoxyquinomicin, a small molecule inhibitor of nuclear factor-κB, on glioblastoma.
    Fukushima T, Kawaguchi M, Yorita K, Tanaka H, Takeshima H, Umezawa K, Kataoka H.
    Neuro Oncol; 2012 Jan 01; 14(1):19-28. PubMed ID: 21968049
    [Abstract] [Full Text] [Related]

  • 36. NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor.
    Kubota T, Hoshino M, Aoki K, Ohya K, Komano Y, Nanki T, Miyasaka N, Umezawa K.
    Arthritis Res Ther; 2007 Jan 01; 9(5):R97. PubMed ID: 17892600
    [Abstract] [Full Text] [Related]

  • 37. Enhancement of the caspase-independent apoptotic sensitivity of pancreatic cancer cells by DHMEQ, an NF-kappaB inhibitor.
    Matsumoto G, Muta M, Umezawa K, Suzuki T, Misumi K, Tsuruta K, Okamoto A, Toi M.
    Int J Oncol; 2005 Nov 01; 27(5):1247-55. PubMed ID: 16211219
    [Abstract] [Full Text] [Related]

  • 38. Regulation of human dendritic cells by a novel specific nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Shinoda K, Nakagawa K, Kosaka T, Tanaka N, Maeda T, Kono H, Mizuno R, Kikuchi E, Miyajima A, Umezawa K, Oya M.
    Hum Immunol; 2010 Aug 01; 71(8):763-70. PubMed ID: 20573582
    [Abstract] [Full Text] [Related]

  • 39. Suppression of hormone-refractory prostate cancer by a novel nuclear factor kappaB inhibitor in nude mice.
    Kikuchi E, Horiguchi Y, Nakashima J, Kuroda K, Oya M, Ohigashi T, Takahashi N, Shima Y, Umezawa K, Murai M.
    Cancer Res; 2003 Jan 01; 63(1):107-10. PubMed ID: 12517785
    [Abstract] [Full Text] [Related]

  • 40. In vivo antitumor activity of the NF-kappaB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia.
    Ohsugi T, Horie R, Kumasaka T, Ishida A, Ishida T, Yamaguchi K, Watanabe T, Umezawa K, Urano T.
    Carcinogenesis; 2005 Aug 01; 26(8):1382-8. PubMed ID: 15831528
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.